Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Long-Term Debt Repayments (2016 - 2017)

Corcept Therapeutics (CORT) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $4.6 million as the latest value for Q3 2017.

  • For Q3 2017, Long-Term Debt Repayments fell 81.84% year-over-year to $4.6 million; the TTM value through Sep 2018 reached $4.6 million, down 89.76%, while the annual FY2017 figure was $15.1 million, 2.4% up from the prior year.
  • Long-Term Debt Repayments hit $4.6 million in Q3 2017 for Corcept Therapeutics, down from $5.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $29.9 million in Q4 2016 and bottomed at $647000.0 in Q4 2013.
  • Average Long-Term Debt Repayments over 5 years is $7.9 million, with a median of $3.8 million recorded in 2016.
  • Year-over-year, Long-Term Debt Repayments soared 981.77% in 2016 and then tumbled 81.84% in 2017.
  • Corcept Therapeutics' Long-Term Debt Repayments stood at $647000.0 in 2013, then soared by 142.35% to $1.6 million in 2014, then skyrocketed by 76.28% to $2.8 million in 2015, then skyrocketed by 981.77% to $29.9 million in 2016, then plummeted by 84.57% to $4.6 million in 2017.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $4.6 million, $5.7 million, and $4.8 million for Q3 2017, Q2 2017, and Q1 2017 respectively.